CoChat

Perioperative ctDNA-Based Molecular Residual Disease Detection for Non–Small Cell Lung Cancer: A Prospective Multicenter Cohort Study (LUNGCA-1)

Xia, Liang, Mei, Jiandong, Kang, Ran, Deng, Senyi, Chen, Yaohui, Yang, Ying, Feng, Gang, Deng, Yulan, Gan, Fanyi, Lin, Yidan, Pu, Qiang, Ma, Lin, Lin, Feng, Yuan, Yong, Hu, Yang, Guo, Chenglin, Liao, Hu, Liu, Chengwu, Zhu, Yunke, Wang, Wenping, Liu, Zheng, Xu, Yuyang, Li, Kaidi, Li, Chuan, Li, Qingyun, He, Ji, Chen, Weizhi, Zhang, Xiaolong, Kou, Yingli, Wang, Yun, Wu, Zhu, Che, Guowei, Chen, Longqi, Liu, Lunxu · 2022 · Clinical Cancer Research
Cited by 244

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Purpose: We assessed whether perioperative circulating tumor DNA (ctDNA) could be a biomarker for early detection of molecular residual disease (MRD) and prediction of postoperative relapse in resected non–small cell lung cancer (NSCLC). Experimental Design: Based on our prospective, multicenter cohort on dynamic monitoring of ctDNA in lung cancer surgery patients (LUNGCA), we enrolled 950 plasma samples obtained at three perioperative time points (before surgery, 3 days and 1 month after surgery) of 330 stage I–III NSCLC patients (LUNGCA-1), as a part of the LUNGCA cohort. Using a customized 769-gene panel, somatic mutations in tumor tissues and plasma samples were identified with next-generation sequencing and utilized for ctDNA-based MRD analysis. Results: Preoperative ctDNA positivity was associated with lower recurrence-free survival (RFS; HR = 4.2; P < 0.001). The presence of MRD (ctDNA positivity at postoperative 3 days and/or 1 month) was a strong predictor for disease relapse (HR = 11.1; P < 0.001). ctDNA-based MRD had a higher relative contribution to RFS prediction than all clinicopathologic variables such as the TNM stage. Furthermore, MRD-positive patients who received adjuvant therapies had improved RFS over those not receiving adjuvant therapy (HR = 0.3; P = 0.008), whereas MRD-negative patients receiving adjuvant therapies had lower RFS than their counterparts without adjuvant therapy (HR = 3.1; P < 0.001). After adjusting for clinicopathologic variables, whether receiving adjuvant therapies remained an independent factor for RFS in the MRD-positive population (P = 0.002) but not in the MRD-negative population (P = 0.283). Conclusions: Perioperative ctDNA analysis is effective in early detection of MRD and relapse risk stratification of NSCLC, and hence could benefit NSCLC patient management.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-21-3044

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 244

Metadata

Authors
Xia, L., Mei, J., Kang, R., Deng, S., Chen, Y., Yang, Y., Feng, G., Deng, Y., Gan, F., Lin, Y., Pu, Q., Ma, L., Lin, F., Yuan, Y., Hu, Y., Guo, C., Liao, H., Liu, C., Zhu, Y., Wang, W., Liu, Z., Xu, Y., Li, K., Li, C., Li, Q., He, J., Chen, W., Zhang, X., Kou, Y., Wang, Y., Wu, Z., Che, G., Chen, L., & Liu, L.
Venue
Clinical Cancer Research
Published
2021-11-22
Volume
28
Issue
15
Pages
3308-3317
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W3217281296
Cited by
244
References
7
FWCI
11.88
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Perioperative ctDNA-Based Molecular Residual Disease Detection for Non–Small Cell Lung Cancer: A Prospective Multicenter Cohort Study (LUNGCA-1). https://app.cochat.ai/papers/10.1158/1078-0432.ccr-21-3044
The paper
Xia, L., Mei, J., Kang, R., Deng, S., Chen, Y., Yang, Y., Feng, G., Deng, Y., Gan, F., Lin, Y., Pu, Q., Ma, L., Lin, F., Yuan, Y., Hu, Y., Guo, C., Liao, H., Liu, C., Zhu, Y., . . . Liu, L. (2022). Perioperative ctDNA-Based Molecular Residual Disease Detection for Non–Small Cell Lung Cancer: A Prospective Multicenter Cohort Study (LUNGCA-1). Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-21-3044

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.